Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin's lymphoma found in children and young adults. ALCLs frequently carry a chromosomal translocation that results in expression of the oncoprotein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). The key molecular downstream events required for NPM-ALK-triggered lymphoma growth have been only partly unveiled. Here we show that the activator protein 1 family members JUN and JUNB promote lymphoma development and tumor dissemination through transcriptional regulation of platelet-derived growth factor receptor-b (PDGFRB) in a mouse model of NPM-ALK-triggered lymphomagenesis. Therapeutic inhibition of PDGFRB markedly prolonged survival of NPM-ALK transgenic mice and increased the efficacy of an ALK-specific inhibitor in transplanted NPM-ALK tumors. Notably, inhibition of PDGFRA and PDGFRB in a patient with refractory late-stage NPM-ALK + ALCL resulted in rapid, complete and sustained remission. Together, our data identify PDGFRB as a previously unknown JUN and JUNB target that could be a highly effective therapy for ALCL.
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ALCLs are T cell lymphomas 1,2 comprising 10-20% of all nonHodgkin's lymphoma cases in children and 3% in adults 3 . About half of ALCL cases are positive for the NPM-ALK fusion chimera caused by the t(2;5)(p23;q35) translocation 4 . ALK translocations or point mutations have also been described in diffuse large B cell lymphomas and in several nonlymphoid neoplasms [5] [6] [7] [8] . Inhibition of ALK fusion proteins by specific compounds such as crizotinib showed promising clinical responses in ALCL and non-small cell lung cancer 9, 10 . However, ALK mutations conferring resistance to crizotinib have also been reported 11 .
Recent studies have linked NPM-ALK expression to induction of the activator protein 1 (AP-1) transcription factors JUNB and JUN 12, 13 . To investigate their role in NPM-ALK-driven T cell lymphomas, we conditionally deleted JUN and/or JUNB in T cells of transgenic mice carrying the human NPM-ALK fusion protein under the control of the mouse CD4 promoter 14 (CD4-NPM-ALK) (Fig. 1a) . We confirmed gene deletion by DNA genotyping (data not shown), real-time PCR, western blotting and immunohistochemistry ( Supplementary  Fig. 1a-c) . JUN deletion did not affect expression of oncogenic NPM-ALK in T cells (Supplementary Fig. 1a-c) , and all genetic cohorts showed normal T cell development before onset of lymphoma ( Supplementary Fig. 1d ,e and data not shown). CD4-NPM-ALK mice developed T cell lymphomas around 8 weeks after birth. The overall survival was not affected by deletion of JUN or JUNB alone (Fig. 1b) , but survival was substantially prolonged in mice in which both JUN 1 7 0 0 VOLUME 18 | NUMBER 11 | NOVEMBER 2012 nature medicine and JUNB were deleted (CD4-NPM-ALK-CD4 ∆∆JUN ) (Fig. 1b) . Lymphomas from CD4-NPM-ALK-CD4 ∆∆JUN mice showed markedly reduced proliferation and significantly (P = 0.014) increased apoptosis compared to lymphomas from CD4-NPM-ALK mice ( Fig. 1c and Supplementary Fig. 2a,b) . Fig. 2c ).
Consistently, CD4-NPM-ALK-CD4
Freshly isolated CD4-NPM-ALK-CD4 ∆∆JUN lymphoma cells formed palpable tumors when engrafted into severe combined immunodeficient (SCID) mice, albeit after a long latency (Supplementary Fig. 2d ). These results show that JUN and JUNB are important regulators of NPM-ALK-driven T cell lymphoma development. T cell lymphomas spread to many organs in CD4-NPM-ALK transgenic mice 14 . Although CD4-NPM-ALK-CD4 ∆∆JUN mice eventually developed lymphomas, we did not detect dissemination of tumor cells (Fig. 1d,e and Supplementary Fig. 2e) . Notably, blood vessel numbers were significantly decreased in primary lymphomas of CD4-NPM-ALK-CD4 ∆∆JUN mice compared to CD4-NPM-ALK controls (Fig. 2a) . Expression and activation of the pericyte marker PDGFRB was readily detectable in lymphoma cells of CD4-NPM-ALK mice but essentially absent in T cell lymphomas of CD4-NPM-ALK-CD4 ∆∆JUN mice (Fig. 2b,c) . Tumor cells from single mice lacking only JUNB or JUN (designated CD4-NPM-ALK-CD4 ∆JUNB and CD4-NPM-ALK-CD4 ∆JUN , respectively) showed intermediate PDGFRB protein expression (Supplementary Fig. 3a) . PDGFRB mRNA expression was also decreased in lymphomas of CD4-NPM-ALK-CD4 ∆∆JUN mice when compared to CD4-NPM-ALK lymphomas (Fig. 2d) , suggesting transcriptional regulation of PDGFRB by JUN proteins. Consistently, AP-1 consensus sequences were identified within the mouse PDGFRB promoter and the first intron and were conserved among other species 15, 16 ( Supplementary Fig. 3b,c) . Analysis of ENCODE transcription factor binding tracks revealed binding of JUN and JUNB to the PDGFRB intronic AP-1 site in the human K562 leukemia cell line 15, 17 ( Supplementary Fig. 3d ). Electrophoretic mobility shift assay analysis of nuclear extracts from NPM-ALK lymphomas demonstrated AP-1 DNA binding to the consensus sequence, which was reduced after antibody-mediated JUN and JUNB depletion (Fig. 2e) . Moreover, binding of JUN and JUNB to the PDGFRB promoter was confirmed by chromatin immunoprecipitation assays of human dermal fibroblasts (Fig. 2f ) , mouse NPM-ALK cell lines and tumor tissues ( Supplementary Fig. 3e,f) and luciferase reporter assays in Jurkat cells (Fig. 2g) and HeLa cells using PDGFRB promoter constructs with and without an AP-1 site (Supplementary Fig. 3g ). These data demonstrate transcriptional regulation of PDGFRB by JUN and JUNB. PDGFRs have not been implicated in ALCL but are known physiologic regulators of tumor growth [18] [19] [20] . We therefore investigated the effects of the PDGFR kinase inhibitor imatinib on established mouse A333, MEL406 and CD4-417 lymphoma cell lines. Imatinib also blocks activity of the BCR-ABL kinase, the receptor tyrosine kinase KIT and PDGFRA with high affinity 21 , but it has no effect on ALK 22, 23 . The NPM-ALK lymphoma cell lines did not express BCR-ABL (data not shown) or PDGFRA, but they expressed KIT at variable levels ( Fig. 3a and Supplementary  Fig. 4a,b) . PDGFRB expression ranged from high to non-detectable ( Fig. 3a and Supplementary Fig. 4a ). We then used tumor cell transplantation experiments to evaluate the effects of imatinib on tumor growth. Notably, imatinib treatment of tumor-bearing mice resulted in markedly reduced tumor growth ( Fig. 3b and Supplementary  Fig. 4c ). The response rate of individual transplanted cell lines correlated with the level of PDGFRB expression, as A333-derived lymphomas (lacking PDGFRB but expressing high levels of KIT) were not affected by imatinib treatment (Fig. 3b) . We obtained similar results using nilotinib (Supplementary Fig. 4d ), another PDGFRB kinase inhibitor 24, 25 . Imatinib treatment did not affect expression of ALCL-associated cytokines and their receptors (such as IL-9 and IL-22 (refs. 26,27; Supplementary Fig. 4e ), peripheral and splenic T cell populations ( Supplementary Fig. 5a -c) or tumor-infiltrating T cell subsets ( Supplementary Fig. 5d,e) . These results indicate that inhibition of PDGFRB markedly impairs growth of transplanted ALCL tumor cells. We next explored the effects of imatinib on primary lymphomas in CD4-NPM-ALK mice. Imatinib treatment substantially increased overall survival (Fig. 3c) , reduced in vivo tumor cell proliferation and enhanced apoptosis (Fig. 3d) . Imatinib also blocked proliferation and enhanced cell death of mouse PDGFRB + lymphoma cell lines in vitro (Supplementary Fig. 6a,b) . As expected, imatinib reduced PDGFRB phosphorylation in CD4-NPM-ALK cell lines (Supplementary Fig. 6c ) and in tumor tissues from CD4-NPM-ALK mice (Fig. 3e) , resulting in reduced phosphorylation of protein kinase B (PKB, also known as AKT) and signal transducer and activator of transcription 3 (STAT3) but not of extracellular signal-regulated kinase (ERK) ( Supplementary  Fig. 6d,e) . Furthermore, PDGFRB phosphorylation in PDGF-β (PDGFB)-stimulated lymphoma cells was impaired by imatinib in a dose-dependent manner (Supplementary Fig. 6f,g ), resulting in reduced proliferation (Supplementary Fig. 6h ). Imatinib also reduced PDGFB mRNA levels ( Supplementary Fig. 6i ) in CD4-NPM-ALK lymphomas, indicating an autoregulatory PDGF secretion loop. Notably, in imatinib-treated CD4-NPM-ALK-CD4 ∆∆JUN mice, no tumors developed during the 30-week observation period (Fig. 3c) , and tumor cell dissemination to distant organs was completely blocked (Supplementary Fig. 7a ). This is probably owing to an additional effect of imatinib on the tumor stroma, which has been reported for other cancers 28, 29 (Supplementary Fig. 7b-f) .
We next tested imatinib treatment in combination with the ALK inhibitor crizotinib 9 . Imatinib and crizotinib synergistically reduced tumor growth of grafted mouse NPM-ALK + lymphoma cells (Fig. 3f) . npg of lymphomas that relapsed after CEP28122 treatment (Fig. 3g,h) . These results show that therapeutic blockade of PDGFRs can markedly alleviate relapse of ALCLs after ALK inhibition.
The vast majority of human NPM-ALK + and NPM-ALK − ALCLs showed high expression of JUNB, JUN, PDGFRA and PDGFRB mRNA [31] [32] [33] [34] (Fig. 4a) and protein ( Fig. 4b and Supplementary  Fig. 8a,b) . In contrast to peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T cell lymphoma (AITL), most ALCL samples showed high expression of both PDGFRA and PDGFRB. Consistently, two highly conserved AP-1 binding sites were identified in the human PDGFRA promoter ( Supplementary  Fig. 8c ). We did not detect wild-type or mutated forms of KIT or BCR-ABL in ALK + lymphomas ( Supplementary Fig. 8d and data not shown). Established human ALK + ALCL cell lines were negative for PDGFRA and PDGFRB (Supplementary Fig. 8e ), but ALK expression was required to maintain JUNB mRNA expression ( Supplementary  Fig. 8f ). These results demonstrate that primary human ALK + ALCLs express high levels of PDGFRA, PDGFRB and JUNB.
On the basis of our results, we tried imatinib treatment in a patient with an ALCL of poor prognosis. This NPM-ALK + , JUNB + , JUN + , PDGFRA + , PDGFRB + , KIT − ALCL (Fig. 4c) was refractory to conventional chemotherapy and relapsed after autologous stem cell transplantation. The patient entered complete clinical remission with reduced tumor markers and diminished PDGFB levels after 10 d of imatinib therapy (Fig. 4d-g ). The patient is now free of ALCL 22 months after initiation of imatinib therapy (Supplementary Case Report). We also observed high PDGFB levels in the serum of four additional patients with ALCL (Supplementary Fig. 8g ).
JUNB and JUN are thus crucial for the growth and metastasis of NPM-ALK + ALCL, exerting this effect through the direct regulation of PDGFR expression. ALK induces the expression of JUNB and JUN 12, 13 , which subsequently bind to and activate the PDGFRB promoter. We show that PDGFR expression and activation is a key driver of ALCL proliferation, lymphoma cell survival and tumor cell dissemination. PDGFRs might promote ALCL formation through a combined effect on lymphoma cells and tumor stroma. The mechanism by which PDGFRs promote ALCL formation in the tumor stroma and the qualitative contribution of stromal effects to drug responses in the mouse models are unclear at present, and further experiments will be required to address these issues. Although the precise mechanism is not fully understood, inhibition of PDGFRB by imatinib resulted in an excellent therapeutic response in the CD4-NPM-ALK ALCL mouse model and in a terminally sick patient with NPM-ALK + ALCL.
Our patient data show that PDGFRs are present in NPM-ALK + T cell lymphomas but also in highly malignant NPM-ALK − ALCL. This would imply that, in the absence of ALK, other kinases drive the expression of PDGFRs, through AP-1 or other transcription factors. It should be noted that we have not proven that PDGFRs functions within the context of the signaling networks in ALK − tumor cells. Future experiments will be required to investigate whether PDGFR expression is a crucial common driver for lymphomagenesis. The major clinical challenge in treating NPM-ALK + ALCL is its high rate of relapse. Notably, we have shown here that the dual inhibition of ALK and PDGFR reduces lymphoma growth and alleviates relapse rates. Our findings suggest that imatinib is a potential therapeutic option for patients with crizotinib-resistant lymphomas 11 .
In summary, we provide evidence that PDGFR inhibition is a highly effective treatment for NPM-ALK + ALCL, and these findings might also be relevant for ALK − lymphomas. We are now designing a clinical trial on the basis of PDGFR expression in tumors, for which we will enroll patients with second-stage ALCL.
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